How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

Topics: Radiation Oncology • Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Johns Hopkins • NCI-CCC GU Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

This patient is now in the salvage setting with PSA recurrence after RP and with PSA persistence and node-positive disease. This is a grey area of medicine without level 1 evidence from RCTs but there are some sources of data to help guide optimal outcomes. This patient is at high risk for further m...

Comments

Medical Oncologist at IHA Hematology Oncology Consultants - Ann Arbor
How long should abiraterone/pred be continued if p...

Medical Oncologist at Duke University School of Medicine
2 years is what was given in the STAMPEDE trial wi...

Answer from: Radiation Oncologist at Community Practice

I largely agree with @Andrew J. Armstrong. This is an area more data is needed.Fortunately, the open and enrolling NRG GU008 is one of the few trials specifically aimed at determining the optimal treatment for pN+ patients post-RP with BCR.The control arm is salvage RT + 2 years of ADT.Experimental ...

Comments

Medical Oncologist at Duke University School of Medicine
Thanks @Daniel E. Spratt and I agree. I like this ...

Radiation Oncologist at Multicare
What dose?

Medical Oncologist at Duke University School of Medicine
Abiraterone is 1,000 mg daily taken an hour before...

Related Questions